Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma

4BIO Ventures III portfolio company Trogenix Ltd, a clinical-stage oncology company engineering programmable immunotherapies, announced that the first patient has been dosed in its Phase I/II clinical trial evaluating TGX-007, a dual-payload adeno-associated virus (AAV)-based gene therapy. It will treat patients with newly diagnosed or recurrent glioblastoma (GBM), one of the most common and aggressive forms of brain cancer. Read more at the company website.